In this article, we will discuss: 20 Best Performing Stocks in 2025.

Reuters reported on January 1, 2026, that U.S. stocks ended a volatile year with double-digit growth, despite weakening on the last trade day of 2025, as thin volumes and profit-taking held markets just below record highs. Global equities remained at all-time highs, but precious metals dipped following unprecedented gains, with gold reaching a 46-year high and silver achieving a record annual jump. “Looking back on it, it was a rather tiring year,” stated Scott Ladner, chief investment officer at Horizon, citing dollar weakness, tariff volatility, and uncertainty in global politics.

Meanwhile, treasury yields increased slightly, with the 10-year yield reaching 4.163%, following data that revealed an unexpected decline in unemployment claims. The dollar was on track for its steepest yearly fall since 2017, weighed down by rate cuts and budget concerns. Oil prices fell by 0.91% to over $57 per barrel in the United States and $61 for Brent, marking the biggest annual decrease since 2020, while Bitcoin plunged by 0.70% to around $87,600.

With that said, here are the 20 Best Performing Stocks in 2025.

Our Methodology

We first sifted through the Finviz stock screener to compile a list of the Best Performing Stocks in 2025. A market cap filter with a value of more than $2 billion was used on the screener. From that list, we selected 20 stocks that had the highest total returns in the past year as of December 31, 2025. We have also mentioned the number of hedge funds that have stakes in them as of Q3 2025. We have ranked our list according to the total returns in 2025 as of 31 December, 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

20. Allied Gold Corporation (NYSE:AAUC)

Total Returns in 2025: 228.7%

Number of Hedge Fund Holders: 7

Allied Gold Corporation (NYSE:AAUC) is among the Best Performing Stocks.

On December 22, 2025, TheFly announced that Allied Gold Corporation (NYSE:AAUC) had started processing ore using the fresh ore comminution circuit built as part of the Phase 1 expansion at Sadiola. The goals of the Phase 1 expansion are to boost output, cut expenses, and significantly improve cash flows.

The company is getting closer to the end of Phase 2 research, which seeks to determine Sadiola’s preferred development trajectory. Such studies include analyzing a progressive, modular, and organic development of current facilities, as well as conducting assessments to improve metallurgical recoveries for fresh ore.

Allied Gold Corporation (NYSE:AAUC) reported on November 5, 2025, that it produced 87,020 ounces of gold during the last quarter and sold 92,099 ounces.

The stock is up by 8.21% YTD as of January 6, 2026.

19. Guardant Health, Inc. (NASDAQ:GH)

Total Returns in 2025: 234.3%

Number of Hedge Fund Holders: 50

Guardant Health, Inc. (NASDAQ:GH) is among the Best Performing Stocks.

On January 5, 2026, TheFly reported that Wall Street firms had given Guardant Health, Inc. (NASDAQ:GH) two price target raises. Subbu Nambi, an analyst at Guggenheim, increased the firm’s price objective for the corporation from $85 to $115 and retained a buy rating. Guggenheim stated that in response to recent updates given during discussions with management teams, it modified models and projections for covered Diagnostics and Life Sciences Tools companies.

Separately, on December 22, 2025, Canaccord maintained its Buy recommendation on Guardant Health, Inc. (NASDAQ:GH) shares and raised its price objective from $100 to $125. Canaccord stated that it expects the sector momentum that started in the second part of the year to be sustained in 2026 and gave an overview of its coverage of life science tools and diagnostics. Canaccord claimed to have the strongest confidence in the company’s risk-reward profile and potential for share price growth among the firms covered.

Guardant Health, Inc. (NASDAQ:GH) is a leader in liquid-based cancer testing for clinical and research applications.

18. ​​Micron Technology, Inc. (NASDAQ:MU)

Total Returns in 2025: 240.2%

Number of Hedge Fund Holders: 105

​​Micron Technology, Inc. (NASDAQ:MU) is among the Best Performing Stocks.

On January 7, 2026, TheFly reported that UBS maintained a Buy rating and boosted its price goal for ​​Micron Technology, Inc. (NASDAQ:MU) from $300 to $400. According to the firm, the corporation management stressed the memory cycle’s longevity, pointing out that artificial intelligence has made DRAM more strategic. UBS also noted that the rapid obsolescence of high-bandwidth memory minimizes customer inventory production. The analyst believes that these variables could promote more sustainable earnings per share and lessen the extreme cyclicality that has previously been observed in the memory industry.

Separately, on the same day, Piper Sandler maintained its Overweight rating on ​​Micron Technology, Inc. (NASDAQ:MU) while increasing its price target from $275 to $400. Piper stated that the supply for calendar year 2026 is effectively sold out, with minimal capacity for expansion. Management stated that pricing for high-value products like HBM4 will be value-based. Given that demand is predicted to continue exceeding supply, Piper noted the company is in an excellent spot.

Micron Technology, Inc. (NASDAQ:MU)  is one of the biggest semiconductor companies in the world.

17. CommScope Holding Company, Inc. (NASDAQ:COMM)

Total Returns in 2025: 248%

Number of Hedge Fund Holders: 52

CommScope Holding Company, Inc. (NASDAQ:COMM) is among the Best Performing Stocks.

CommScope Holding Company, Inc. (NASDAQ:COMM) announced the introduction of its new RUCKUS MDU package, which includes Wi-Fi 7 and AI-driven solutions for multi-dwelling unit settings. The suite, which is based on the RUCKUS One platform, supports more devices per unit, lowers latency, increases reliability, and requires less human troubleshooting by combining cloud-based automation with enterprise-level Wi-Fi analytics. The RUCKUS One MDU 360 platform uses AI-driven analytics, predictive insights, and role-based access to give property owners and managed service providers a single picture of network health, resident experience, and service-level performance across portfolios. The RUCKUS Digital System Engineer is an AI-driven helper integrated into RUCKUS. One that lets customers manage home networks using natural language queries, automatically creates dashboards, and provides data-driven insights. The suite also comprises RUCKUS H670 and R575 Wi-Fi 7 access points, which provide multi-gigabit performance with integrated Bluetooth Low Energy and Zigbee radios that enable Matter and Thread.

Separately, on November 11, 2025, TheFly reported that BofA maintained a Buy rating for CommScope Holding Company, Inc. (NASDAQ:COMM). It increased its price target from $20 to $23.50, making changes after selling its Connectivity and Cable Solutions segment.

CommScope Holding Company, Inc. (NASDAQ:COMM) provides infrastructure services for communication, data center, and entertainment systems.

16. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Total Returns in 2025: 253.1%

Number of Hedge Fund Holders: 40

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is among the Best Performing Stocks.

On December 17, 2025, TheFly reported that Piper Sandler maintained its Overweight rating for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) and lifted its price objective from $70 to $100. The company has introduced Redemplo for Familial Chylomicronemia Syndrome, as stated by analyst Edward Tenthoff. Piper anticipates at least $625,000 in U.S. FCS sales in Q4 2025 and $12.3 million in 2026. The business stated that these projections could be conservative due to Redemplo’s greater potency, quarterly dosing schedule, and $60,000 lower yearly price compared to Ionis’ Tryngolza. Furthermore, Piper showed confidence that the firm will disclose positive Phase III Redemplo data in cases of severe hypertriglyceridemia in Q3 2026, with the possibility of a blockbuster label expansion in 2027.

Separately, on January 7, 2026, Morgan Stanley maintained its Equal Weight rating while increasing its price objective for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)  from $48 to $81. The firm noted early ARO-INHBE and ARO-ALK7 monotherapy data, claiming that the findings verify the fat loss objective and show prospects in obesity, which it sees as an additional value driver.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is an American biotechnology firm.

15. Opendoor Technologies Inc. (NASDAQ:OPEN)

Total Returns in 2025: 264.3%

Number of Hedge Fund Holders: 30 

Opendoor Technologies Inc. (NASDAQ:OPEN) is among the Best Performing Stocks.

According to a post by Chief Growth Officer Morgan Brown, Opendoor Technologies Inc. (NASDAQ:OPEN) announced the acquisition of Homebuyer.com on December 24, 2025. As stated by Brown, the deal helps the company’s goals of addressing mortgage options along with homeownership. Dan Green, the founder of Homebuyer.com, will join the corporation as Director of Mortgage Growth as part of the transaction, bringing his experience in the field to assist in expanding its mortgage capabilities.

Separately, Opendoor Technologies Inc. (NASDAQ:OPEN) announced two executive positions, as reported by TheFly on December 15, 2025. Lucas Matheson will take over as President on December 22, 2025. Matheson, who most recently held the position of CEO of Coinbase Canada, will be in charge of Corporate Development, Financial Planning & Analysis, and new strategic projects, such as investigating blockchain technology and tokenization in relation to homeownership. With effect from January 1, 2026, Christy Schwartz has been appointed Chief Financial Officer. Schwartz was chosen after an external search and had previously held the position of interim CFO. As Chief Technology and Product Officer, Shrisha Radhakrishna will continue to oversee Engineering, Product, Design, and Data within the company.

Opendoor Technologies Inc. (NASDAQ:OPEN) operates an end-to-end real estate platform that allows users to sell and buy homes online.

14. Centrus Energy Corp. (NYSE:LEU)

Total Returns in 2025: 264.4%

Number of Hedge Fund Holders: 31

Centrus Energy Corp. (NYSE:LEU) is among the Best Performing Stocks. 

On December 24, 2025, TheFly reported that UBS said Centrus Energy Corp. (NYSE:LEU)’s launch of centrifuge manufacturing shows escalating demand for uranium enrichment to maintain the existing U.S. reactor fleet and projected electricity needs from artificial intelligence data centers in the 2030s. The company stated that beyond 2027, a U.S. import prohibition on Russian enrichment volumes is anticipated to put a higher priority on growing domestic enrichment supply. UBS considers the corporation to be well-positioned for the long term due to the long-term nature of its capacity build-out, and the firm is likely to receive considerable Department of Energy investment. UBS retains a $245 price target and a neutral rating.

Separately, TheFly reported on January 6, 2026, that BofA boosted its price objective for Centrus Energy Corp. (NYSE:LEU) from $285 to $340 and kept a Neutral rating following the company’s designation as one of three beneficiaries of $900 million in funding for nuclear fuel capacity from the Department of Energy. The funds will finance the building of new high-assay low-enriched uranium capacity in the United States. BofA noted that the award fell short of its previous model expectation.

Centrus Energy Corp. (NYSE:LEU) engages in providing nuclear fuel and services for the nuclear power industry.

13. Ondas Holdings Inc. (NASDAQ:ONDS)

Total Returns in 2025: 281.2%   

Number of Hedge Fund Holders: 20

Ondas Holdings Inc. (NASDAQ:ONDS) is among the Best Performing Stocks.

On January 02, 2026, The Fly reported that Ondas Holdings Inc. (NASDAQ:ONDS) has declared that it plans to rename itself as Ondas Inc. The company’s present structure as an integrated, globally operating platform is meant to be reflected in the transition. Furthermore, it moved its corporate headquarters to West Palm Beach, Florida. The goal of the move is to facilitate the business’s upcoming expansion. According to Eric Brock, chairman and CEO, the previous name represented a different phase of development. He stated that the company currently functions as a scalable defense and security-related platform for both government and commercial customers. The business model targets international dual-use markets and consists of integrated manufacturing, activities, services, and solutions.

Separately, Ondas Holdings Inc. (NASDAQ:ONDS) received fresh purchase orders worth $10 million for its portfolio of autonomous systems on December 31, 2025. The orders cover counter-UAS solutions for critical infrastructure providers. They also comprise robotic ground platforms and integrated autonomous drone systems. Government security agencies are the systems’ clients. The announcements were made after the deadline.

Ondas Holdings Inc. (NASDAQ:ONDS) creates, develops, produces, sells, and supports FullMAX Software Defined Radio technologies across the United States, Israel, and India.

12. Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

Total Returns in 2025: 283.2%

Number of Hedge Fund Holders: 33

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is among the Best Performing Stocks.

On January 5, 2026, TheFly reported that Needham analyst Ami Fadia kept a Buy recommendation on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) and lifted the price objective from $315 to $460. Needham anticipates more new medication application filings in 2026, which he sees as a continuation of 2025 for the stock. Furthermore, the firm stated that if ulixacaltamide is given priority evaluation, citing unmet medical need, the corporation may be approved for the treatment of essential tremor. Needham anticipates strong growth in 2026 due to several data catalysts and possible approval.

Separately, on December 29, 2025, after Praxis Precision Medicines, Inc. (NASDAQ:PRAX) declared that the FDA had granted Breakthrough Therapy Designation for ulixacaltamide for the treatment of patients with essential tremor, Jefferies analyst Andrew Tsai called the announcement basically reducing risk and significant FDA validation. Since it can be presumed that the FDA has vetted the data package, which includes two positive Phase 3 studies. The firm upgrades its evaluation of ulixacaltamide’s chances of success in essential tremor from 70% to 80%-90%, pointing out that programs using BTD had a high 73% approval rate. Jefferies has a $450 price objective for the company’s shares and a buy rating.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical firm.

11. Bloom Energy Corporation (NYSE:BE)

Total Returns in 2025: 291.2%   

Number of Hedge Fund Holders: 64

Bloom Energy Corporation (NYSE:BE) is among the Best Performing Stocks.

Forbes reported on January 5, 2026, that following market reactions to an existing $600 million credit line, Bloom Energy Corporation (NYSE:BE) shares rose 14%. Trading volume increased in line with the price movement. The reaction came after the market had recovered from a December fall and shortly after the credit facility had been disclosed. The company’s financial situation is anticipated to be strengthened by the credit facility, which also lowers the risk associated with future expansion plans. It offers financial flexibility for prospective purchases and capital expenditures. Energy-intensive data centers and other AI-related infrastructure are tied to the company’s growing power requirements. Revenue growth is linked to rising energy demand due to AI use. The firm declared a gross margin of 31.2% and a negative pre-tax profit margin of 14.8%.

TheFly reported on December 29, 2025, that Clear Street maintained its Hold rating on Bloom Energy Corporation (NYSE:BE) shares and increased the price target to $58 from $50. To account for the possibility that the firm may add more internal production capacity for datacenter products, the company raised its revenue estimate for 2026 by 2% and its revenue estimate for 2027 by 9% to $3.33 billion. The company maintains a Hold recommendation based on valuation. Although it still appreciates the corporation’s specialty and large market share for its onsite power generation and uptime dependability benefits for new datacenters and manufacturing activities.

Bloom Energy Corporation (NYSE:BE) is positioned as an important player in the energy transformation.

10. Viasat, Inc. (NASDAQ:VSAT)

Total Returns in 2025: 304.9%  

Number of Hedge Fund Holders: 31

Viasat, Inc. (NASDAQ:VSAT) is among the Best Performing Stocks.

On December 15, 2025, TheFly reported that Viasat, Inc. (NASDAQ:VSAT) disclosed a next-generation Ka-band satellite communications network for government customers, which incorporates Viasat Ka-band satellites, the Global Xpress fleet, and select partner satellites into a fully integrated worldwide network that is interoperable with MILSATCOM Ka-band systems. The network allows seamless multi-orbit connectivity spanning air, land, and sea, allowing for roaming across Global Xpress, Viasat, and other Ka-band satellites using improved single-terminal solutions. It employs an integrated waveform, improved gateways, and a common ground architecture to enable data rates of up to 200 Mbps via a 45cm antenna, dynamically assigned bandwidth, and specially designed secure connectivity. ViaSat-3 satellites, such as the recently launched ViaSat-3 F2 for the Americas and the upcoming ViaSat-3 F3 for Asia-Pacific coverage, are part of the network.

Separately, on December 11, 2025, South Korea’s Innospace chose Viasat, Inc. (NASDAQ:VSAT)‘s InRange launch telemetry service. It is a component of the HaloNet portfolio to assist a HANBIT-Nano mission that is transporting eight payloads from Brazil to low Earth orbit. The mission will provide compressed video streaming and telemetry data.

 Viasat, Inc. (NASDAQ:VSAT) offers bandwidth technologies and services.

9. Lumentum Holdings Inc. (NASDAQ:LITE)

Total Returns in 2025: 339%

Number of Hedge Fund Holders: 69

Lumentum Holdings Inc. (NASDAQ:LITE) is among the Best Performing Stocks.

In mid-December, Wall Street firms raised their price targets for the company on multiple occasions. TheFly on December 16, 2025, reported that BofA kept its Neutral rating while increasing its price target for the corporation from $210 to $375. The firm stated that it raised its goals for Lumentum Holdings Inc. (NASDAQ:LITE) and Coherent considerably because of the excessive demand for optical transceivers and components, pointing out that supply is still falling short of demand in those areas.

Separately, on December 17, 2025, Morgan Stanley maintained its Equal Weight recommendation on the shares and raised its price objective for Lumentum Holdings Inc. (NASDAQ:LITE) from $190 to $304. The company claimed that in 2025, the AI trade expanded beyond semiconductor equities, helping infrastructure firms, especially those in the optical market. Morgan Stanley anticipates that trend, particularly for optical names, to persist through the first half of 2026.

The stock is up by 4.72% YTD as of January 6, 2025.

Lumentum Holdings Inc. (NASDAQ:LITE) is a California-based technology company.

8. Cogent Biosciences, Inc. (NASDAQ:COGT)

Total Returns in 2025: 355.4%   

Number of Hedge Fund Holders: 44

Cogent Biosciences, Inc. (NASDAQ:COGT) is among the Best Performing Stocks.

Based on a research note dated January 6, 2026, The Fly reported that H.C. Wainwright reaffirmed a Buy rating and lifted its price target for Cogent Biosciences, Inc. (NASDAQ:COGT) from $50 to $52. The firm stated that it anticipated an uneventful FDA review procedure for bezuclastinib in cases of non-advanced systemic mastocytosis.

Cogent Biosciences, Inc. (NASDAQ:COGT) filed a New Drug Application for bezuclastinib in NonAdvanced Systemic Mastocytosis with the US Food and Drug Administration on December 30, 2025. This submission comes after the Breakthrough Therapy Designation for bezuclastinib in patients with smoldering systemic mastocytosis and NonAdvSM patients who were previously treated with avapritinib. It is based on favorable clinical data from the SUMMIT pivotal trial. All of the major and important secondary outcomes of the SUMMIT study were statistically significant. Bezuclastinib exhibited a therapeutic effect in every symptom domain, including improvements in the most severe baseline symptom as well as 11 patient-specific symptoms. Improvements in symptoms were associated with decreases in serum tryptase. Updated 48-week data revealed that the improvement in symptoms continued to deepen with time. Bezuclastinib showed a profile of safety.

Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology business that specializes in creating precision treatments for diseases that are determined by genetics.

7. Aris Mining Corporation (NYSE:ARMN)

Total Returns in 2025: 363.7%

Number of Hedge Fund Holders: – 

Aris Mining Corporation (NYSE:ARMN) is among the Best Performing Stocks.

On December 12, 2025, Aris Mining Corporation (NYSE:ARMN) declared that it had successfully acquired the remaining 49% stake in the Soto Norte joint venture in Colombia from MDC Industry Holding Company LLC (Mubadala). Following the deal, Mubadala was no longer given the related precious metals stream, and the corporation currently controls 100% of the Soto Norte Project.

According to its CEO, Neil Woodyer, the firm is concentrating on establishing an extensive gold business across Colombia and Guyana now that it owns Segovia, Marmato, Toroparu, and Soto Norte entirely. He stated that the approach focuses on significant cash flow production from existing mines as well as growth through developments, research, and project development.

Woodyer continued that since its founding in 2022, Aris Mining Corporation (NYSE:ARMN) has shifted from a buy-and-build strategy to growing its owned assets and has established a path toward delivering more than one million ounces annually throughout its existing asset base.

On November 3, 2025, TheFly revealed that Don DeMarco, an analyst at National Bank, increased his price objective for Aris Mining Corporation (NYSE:ARMN) from C$22.50 to C$23. It maintains an Outperform rating for the stock.

Aris Mining Corporation (NYSE:ARMN) acquires, explores, develops, and operates gold properties in Colombia, Guyana, and Canada.

6. EchoStar Corporation (NASDAQ:SATS)

Total Returns in 2025: 374.7%  

Number of Hedge Fund Holders: 79 

EchoStar Corporation (NASDAQ:SATS) is among the Best Performing Stocks.

On December 19, 2025, TheFly reported that Deutsche Bank boosted its price objective for EchoStar Corporation (NASDAQ:SATS) to $131 from $97. It maintained a Buy rating in a research note. The firm believes the shares have a 28% upside potential, citing strong catalysts like the prospective sale of EchoStar’s AWS-3 paired spectrum. The closure of the Dish creditor case, potential deals with tower providers, and a future SpaceX IPO were among the other catalysts noted by Deutsche Bank. The firm claimed that it remains convinced that Verizon and T-Mobile are interested in the company’s paired AWS-3 spectrum licenses.

In a separate research note dated December 23, 2025, Citi analyst Michael Rollins lifted Citi’s price objective on EchoStar Corporation (NASDAQ:SATS) from $87 to $111 and retained a Neutral rating. Citi referenced recent news reports speculating that SpaceX may be valued at $800 billion in private due to an impending secondary share offering. According to the firm, this estimated valuation would be roughly twice the pre-tax value of the cost basis for the SpaceX shares that the corporation anticipates receiving after its pending spectrum sales are closed.

EchoStar Corporation (NASDAQ:SATS) designs, develops, and distributes digital set-top boxes and solutions for direct-to-home satellite service providers.

5. Planet Labs PBC (NYSE:PL)

Total Returns in 2025: 388.1%   

Number of Hedge Fund Holders: 40

Planet Labs PBC (NYSE:PL) is among the Best Performing Stocks.

According to a research note dated December 17, 2025, TheFly reported that Goldman Sachs lifted its price target on Planet Labs PBC (NYSE:PL) from $10.90 to $12.30 and retained a Neutral rating. The firm reported third-quarter results that were better than anticipated. Furthermore, per Goldman Sachs, the corporation has recently secured contracts with the U.S. Navy, NASA, and the National Geospatial-Intelligence Agency. The firm also stated that Google and Planet Labs have teamed up to launch prototype satellites for the placement of data centers in space.

In a research note dated December 29, 2025, Clear Street increased its price target on Planet Labs PBC (NYSE:PL) from $16 to $22. It also kept a Buy rating. The company has the potential for more than 20% growth in sales and profit expansion, as stated by analyst Greg Pendy. As reported by Clear Street, the company’s combination of innovative artificial intelligence and its own imagery from satellites supports this prognosis. The corporation plans to maintain profitability and reinvest its cash flow into expansion over the next two years, as per the firm. Clear Street identified a path toward reaching the Rule of 40 and defined this period as a change in corporate maturity. The firm added that Rule of 40 software and data businesses are usually given premium valuations.

Planet Labs PBC (NYSE:PL) is an earth imaging corporation.

4. TMC the metals company Inc. (NASDAQ:TMC)

Total Returns in 2025: 450.9%  

Number of Hedge Fund Holders: 19

TMC the metals company Inc. (NASDAQ:TMC) is among the Best Performing Stocks.

On December 23, 2025, the NYTimes reported that the Trump administration announced that it had received an application for seabed mining exploration in international waters, marking the start of the mining industry’s advancement. TMC the metals company Inc. (NASDAQ:TMC), which has stated that it aims to begin commercial mining operations in the Pacific Ocean in 2027, is formally submitting requests for permits to the federal government. NOAA made the applications available for public comment and scheduled public hearings for late January, noting that it intended to examine them without delay. The Law of the Sea is a treaty that the United States has not ratified, and it governs mining in international waters. The United States is not part of the International Seabed Authority.

Seabed nodules contain nickel, cobalt, manganese, and copper, which are employed in clean energy technology, but the administration has prioritized national security concerns. The Canadian-based TMC the metals company Inc. (NASDAQ:TMC) carried out a mining test in the Clarion-Clipperton Zone in 2022 and currently has exploration permissions from the Seabed Authority. There are unresolved jurisdictional challenges because the U.S. application overlaps with current permissions. Environmental opposition is still widespread, with scientists voicing concerns about the effects on biodiversity and nearly forty different countries demanding a ban. The corporation has funded an environmental study and claims that the necessary data is ready.

TMC the metals company Inc. (NASDAQ:TMC) is a deep-sea mineral exploration firm that specializes in gathering, processing, and refining polymetallic nodules that are discovered on the seafloor in the Clarion Clipperton Zone’s international waters.

3. Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

Total Returns in 2025: 629.2% 

Number of Hedge Fund Holders: 29

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is among the Best Performing Stocks.

On December 11, 2025, TheFly reported that Citizens boosted its price goal for Terns Pharmaceuticals, Inc. (NASDAQ:TERN) to $57 from $35. The firm retained an Outperform rating, noting interim Phase 1 CARDINAL ASH data confirming a best-in-class profile for TERN-701. The firm identified strong activity after asciminib and ponatinib, which it considers favorable for second-line use, and a high deep molecular response rate that supports first-line potential.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) released third-quarter 2025 results and corporate updates, pointing out that an ASH 2025 abstract featured unprecedented Phase 1 CML efficacy data and a possible best-in-disease profile for TERN-701. An expanded and updated CARDINAL dataset is anticipated to be included in an upcoming ASH oral presentation.

Separately, the firm reported $295.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025, down from $358.2 million as of December 31, 2024. The company stated that current funds are anticipated to cover planned operating costs until 2028.

Nonetheless, the stock is down by 3.07% as of January 6, 2026.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical business.

2. Celcuity Inc. (NASDAQ:CELC)

Total Returns in 2025: 661.9%  

Number of Hedge Fund Holders: 31            

Celcuity Inc. (NASDAQ:CELC) is among the Best Performing Stocks.

On December 12, 2025, TheFly reported that Wells Fargo started covering Celcuity Inc. (NASDAQ:CELC) with a $126 price target and an Overweight rating. According to the firm, Phase 1 data and results from the wild-type cohort have significantly reduced the risk associated with the impending VIKTORIA-1 PIK3CA mutant readout. Wells Fargo also stated that the current share price is not reflecting gedatolisib’s market potential in breast cancer. Metastatic castration-resistant prostate cancer is an additional upside alternative.

Separately, as it moves forward with accelerated launch preparations, Celcuity Inc. (NASDAQ:CELC) reported peak revenue potential for gedatolisib of $2.5 billion to $3 billion in the most recent quarter. The firm noted the release of top-line data from the PIK3CA wild-type group of the Phase III VIKTORIA-1 study and discussed progress on clinical and regulatory objectives.

The PIK3CA mutant cohort wrapped up enrolling, and results are anticipated in late Q1 or Q2 2026. The company’s NDA submission under the real-time oncology review program was approved by the FDA, and it is anticipated to be finished this quarter.

The median progression-free survival for the gedatolisib triplet was 9.3 months, compared to 2 months for fulvestrant, with a hazard ratio of 0.24, as reported by Celcuity Inc. (NASDAQ:CELC). The corporation had over $455 million in cash, cash equivalents, and short-term investments at the end of the quarter, despite reporting a $43.8 million net loss.

Celcuity Inc. (NASDAQ:CELC) is a biotechnology business in the clinical stage that is working on oncology development.

1. ABIVAX Société Anonyme (NASDAQ:ABVX)

Total Returns in 2025: 1,742.2% 

Number of Hedge Fund Holders: 56

ABIVAX Société Anonyme (NASDAQ:ABVX) is among the Best Performing Stocks.

According to a story in the French-language newspaper La Tribune on December 24, 2025, there have been rumors that Eli Lilly has been drawing interest in the French biotechnology business ABIVAX Société Anonyme (NASDAQ:ABVX, TheFly reported. Its shares surged after the release, rising $4.62, or 3%, to $142.97 in pre-market trade in New York.

The company also declared that it was going to be included in the Nasdaq Biotechnology Index. The inclusion went into effect on Monday, December 22, 2025.

Thefly revealed on December 18, 2025, that Guggenheim analyst Yatin Suneja has increased the company’s price objective for ABIVAX Société Anonyme (NASDAQ:ABVX) from $150 to $175. The analyst maintained a Buy rating for the stock. Guggenheim’s positive forecast for obefazimod ahead of an impending 44-week maintenance readout is the basis for the price target hike.

The firm has €589.7 million in cash despite high R&D-driven losses and a €15.3 million monthly cash burn.

Nonetheless, the stock is down by 10.04% YTD as of January 6, 2026.

The goal of ABIVAX Société Anonyme (NASDAQ:ABVX), a clinical-stage biotechnology company, is to develop novel treatments that utilize the body’s own regulatory systems to modulate the immune response in individuals with chronic inflammatory conditions.

While we acknowledge the potential of ABVX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABVX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stock To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. 20 Best Performing Stocks in 2025 is originally published on Insider Monkey. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.